Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Paul S. Covington"'
Autor:
Brian E. Lacy, Lucinda A. Harris, Lin Chang, Susan Lucak, Catherine Gutman, Leonard S. Dove, Paul S. Covington, Anthony Lembo
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 12 (2019)
Background: Irritable bowel syndrome with diarrhea (IBS-D) is a prevalent gastrointestinal (GI) disorder with a varied presentation, often overlapping with other GI and non-GI disorders. Eluxadoline is a locally active mixed µ- and κ-opioid recepto
Externí odkaz:
https://doaj.org/article/14c088d70438411f8b19cdbc07a52190
Publikováno v:
Neurogastroenterology and Motility
Background Recurring abdominal pain is a characteristic and often unpredictable and debilitating symptom of irritable bowel syndrome with diarrhea (IBS‐D). Measuring the effects of IBS‐D treatments on abdominal pain remains a significant challeng
Publikováno v:
Clinical Pharmacology in Drug Development
This study evaluated the effects of eluxadoline, a mixed μ‐opioid receptor (OR) and κ‐OR agonist and δ‐OR antagonist, on cardiac repolarization. This evaluator‐blinded, placebo‐ and positive‐controlled, 4‐period crossover study rando
Publikováno v:
Journal of Clinical Pharmacology
Autor:
Paul S. Covington, William D. Chey, Anthony Lembo, Brian E. Lacy, Brooks D. Cash, Leonard S. Dove
Publikováno v:
The American Journal of Gastroenterology
Objectives: Irritable bowel syndrome with diarrhea (IBS-D) is often managed with over-the-counter therapies such as loperamide, though with limited success. This analysis evaluated the efficacy of eluxadoline in patients previously treated with loper
Publikováno v:
Alimentary Pharmacology & Therapeutics
ummary Background The mixed μ- and κ-opioid receptor agonist and δ-opioid receptor antagonist, eluxadoline, is licensed in the USA for the treatment of irritable bowel syndrome with diarrhoea (IBS-D), based on the results of two large Phase 3 clin
Publikováno v:
The American Journal of Gastroenterology
Objectives: Eluxadoline is a mixed μ-opioid receptor (OR) and κ-OR agonist and δ-OR antagonist, approved for the treatment of irritable bowel syndrome with diarrhea (IBS-D). This analysis evaluated the safety and tolerability of eluxadoline 75 and
Autor:
Lisa Turner, Brian E. Lacy, Marc J. Zuckerman, Anthony Lembo, Rocio Lopez, Paul S. Covington, David Andrae, Leonard S. Dove, J. Michael Davenport, Ron Schey, Gail McIntyre
Publikováno v:
New England Journal of Medicine. 374:242-253
Background Effective and safe treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea. We conducted two phase 3 trials to assess the efficacy and safety of eluxadoline, a new oral agent with mixed opioid effects (μ-
Publikováno v:
American Journal of Gastroenterology. 114:1177-1178
Publikováno v:
Journal of Clinical Pharmacology
The effects of OATP1B1, OAT3, and MRP2 on the pharmacokinetics of eluxadoline, an oral, locally active, opioid receptor agonist/antagonist being developed for treatment of IBS-d were assessed in vivo. Coadministration of a single 200 mg dose of eluxa